ArticleBritish journal of pharmacology2020

LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.

Zhe Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.